Is MCT Oil Good for Fatty Liver Disease?

MCT oil shows real promise for reducing liver fat in animal studies, but no human clinical trial has yet confirmed that it treats or reverses fatty liver disease. The evidence so far comes almost entirely from experiments in mice and rats, where medium-chain triglycerides have consistently lowered liver fat, improved liver enzyme levels, and reduced inflammation. That is encouraging, but it leaves a significant gap between what happens in a rodent’s liver and what a doctor can confidently recommend to a patient with non-alcoholic fatty liver disease (NAFLD).

What Happens in Fatty Liver Disease

Fatty liver disease boils down to a supply-and-demand mismatch. The liver takes in fatty acids from the blood and also builds new fats on its own through a process called de novo lipogenesis. Normally, the liver clears fats just as fast by burning them for energy or packaging them for export. In NAFLD, the intake and production side outpaces the disposal side, and fat accumulates in liver cells.¹ Over time, this overload can stress cells, damage mitochondria, and trigger inflammation, pushing the disease from simple fat accumulation toward a more dangerous stage involving scarring and cell death.²

The question with MCT oil is whether swapping in a different type of dietary fat can tilt that balance back toward disposal, essentially giving the liver a fat it can burn more easily and that is less likely to pile up.

Why MCT Oil Behaves Differently from Other Fats

Most dietary fats are long-chain triglycerides, the kind found in olive oil, butter, and the fat on a steak. Their fatty acid chains are 14 to 22 carbons long. MCT oil is made up of medium-chain fatty acids, mainly caprylic acid (8 carbons, or C8) and capric acid (10 carbons, or C10), which are substantially shorter and more water-soluble.³ That difference in size changes how the body handles them. Long-chain fats travel through the lymphatic system and can circulate in the blood for hours before reaching the liver. Medium-chain fats go almost directly to the liver via the portal vein and are burned for energy rapidly.

Classic research in rats showed that the liver oxidizes caprylic acid roughly four times faster than palmitate, a common long-chain fat.⁴ Because medium-chain fats are burned so quickly, they tend to produce ketone bodies rather than getting stored. In theory, a fat the liver burns on arrival instead of stockpiling could ease the very imbalance that drives fatty liver disease.

What Animal Studies Actually Show

The animal data is where the real excitement sits, and it is surprisingly consistent across different labs and study designs. In one mouse study, obese animals on a high-fat diet supplemented with MCTs (predominantly C8 and C10) showed significantly reduced liver fat, improved liver enzyme levels, and lower expression of inflammation-related genes. The improvement was comparable to what happened in obese mice switched to a low-fat diet.⁵ That is a striking result: adding MCTs to a high-fat diet brought liver health markers down to levels you would expect from cutting the fat content of the diet entirely.

A separate study comparing MCT supplements to common vegetable oils like palmitic and oleic acid found that MCTs reduced liver fat accumulation to a greater degree than the alternatives, and the animals also gained less weight and had better blood lipid profiles.⁶ In a rat model, increasing the proportion of MCTs in the diet dose-dependently reduced liver fat and appeared to boost fat-burning activity by activating a receptor called PPARα.⁷

One particularly interesting finding is that the fat reduction in the liver appeared to be independent of weight loss. In a study using high-fat diets enriched with medium-chain fatty acids, liver triglyceride levels dropped even without the animals losing weight.⁸ That detail matters because the standard clinical advice for fatty liver is to lose weight. If MCTs can reduce liver fat through a separate pathway, they could be helpful even in people who struggle to lose weight or who have already plateaued.

How MCTs Appear to Protect the Liver

Multiple mechanisms seem to work in parallel, which may explain why the effects in animal studies are relatively robust. One pathway involves the toxic lipid species ceramide and diacylglycerol. These are not just inert storage fats; they actively interfere with insulin signaling and drive inflammation. In the mouse study mentioned earlier, MCT supplementation markedly lowered hepatic levels of both ceramide and diacylglycerol and prevented a damaging enzyme from relocating to the cell membrane, where it contributes to insulin resistance.⁵

Another mechanism involves bile acid signaling. MCTs appear to upregulate a receptor called FXR in the liver, which in turn suppresses genes responsible for building new triglycerides.⁶ Essentially, MCTs may tell the liver to slow down its fat production machinery. In the rat model, medium-chain fats also stimulated fat-burning through PPARα activation and boosted mitochondrial respiration, meaning the liver was not only making less new fat but also burning existing fat more efficiently.⁷

There is also evidence that MCTs protect the liver indirectly by shoring up the gut barrier. When the intestinal lining becomes leaky, bacterial toxins called endotoxins can escape into the bloodstream and reach the liver, provoking inflammation. In rats exposed to endotoxin, MCTs blunted the resulting spike in the liver enzyme ALT by about 90% compared to controls.⁹ A separate study on alcohol-induced liver injury found that MCTs normalized levels of circulating endotoxin and restored key tight-junction proteins in the intestinal lining that alcohol had degraded.¹⁰ This gut-liver connection is relevant for NAFLD too, since gut-derived inflammation is increasingly recognized as a contributor to disease progression.

Beyond Fat Accumulation: Effects on Fibrosis

Fatty liver disease becomes dangerous when it progresses to fibrosis, the stage where scar tissue begins replacing healthy liver tissue. A recent study looked specifically at whether medium-chain fatty acids can slow this process. Mice fed an MCFA-rich diet showed significant improvement in liver fibrosis along with reduced fat accumulation. The researchers traced the effect to capric acid (C10), which inhibited the activation and collagen production of hepatic stellate cells, the cells responsible for laying down scar tissue.¹¹

If this holds up, it would be particularly significant because most dietary interventions studied for NAFLD focus on reducing fat in the liver at the steatosis stage. Fewer have shown direct effects on fibrosis, which is the stage most closely linked to serious outcomes like cirrhosis and liver failure. The finding is preliminary, though, and comes from a single set of experiments in mice and cultured human cells.

The Gap Between Animal Evidence and Human Guidance

Despite the consistent animal results, no randomized controlled trial in humans has tested MCT oil specifically as a treatment for NAFLD. There is some human research on MCTs and metabolic health more broadly. A review of the evidence links MCT intake to improved glucose homeostasis, slightly increased energy expenditure and satiety, and modest weight loss.¹² However, a small feasibility study looking at MCT supplementation for insulin sensitivity found no significant changes in fasting glucose, insulin, insulin resistance, or a range of other metabolic markers.¹³ The metabolic benefits, in other words, look real in some contexts but are not dramatic or universal in humans.

Current clinical guidelines for managing NAFLD, like those published jointly by European liver, diabetes, and obesity societies, recommend energy restriction and a dietary pattern resembling the Mediterranean diet. They do not mention MCT oil as a treatment.¹⁴ The Mediterranean diet emphasizes olive oil (a long-chain fat), vegetables, whole grains, fish, and nuts. MCT oil does not conflict with this pattern, but it is not part of the recommendation either.

Coconut Oil Is Not the Same as MCT Oil

This distinction trips up a lot of people. Coconut oil contains some medium-chain fatty acids, but roughly half of its fat is lauric acid (C12), which behaves more like a long-chain fat metabolically. Pure MCT oil is typically refined to contain mostly C8 and C10, the chains that travel straight to the liver and burn rapidly. When researchers fed mice coconut oil, levels of multiple medium-chain fatty acids including C8, C10, and C12 increased in the liver.¹⁵ But coconut oil also delivers a large load of longer saturated fats, which can work against you in the context of fatty liver.

The animal studies showing clear liver benefits used purified MCTs, not coconut oil. If you are considering trying MCT oil for liver health, the concentrated C8/C10 form is the one with supporting evidence. Treating coconut oil as an equivalent substitute is a common and potentially counterproductive mistake, since the additional long-chain saturated fats could contribute to the very lipid overload you are trying to reduce.

Practical Considerations If You Decide to Try It

MCT oil is sold as a dietary supplement and is widely available. Typical doses in studies range from one to two tablespoons per day, often mixed into coffee, smoothies, or dressings. Starting at the low end is wise because MCT oil can cause digestive discomfort, particularly cramping and diarrhea, when introduced too quickly. Most people adjust within a week or two.

A few things worth keeping in mind:

Calories still count: MCT oil has about 100 calories per tablespoon. If you add it on top of your existing diet without reducing other fats or calories, you are adding energy, which works against the goal of reducing liver fat. The animal studies showing benefit typically replaced other dietary fats with MCTs rather than simply adding MCTs on top.
Weight loss remains first-line: Losing even a modest amount of body weight is the most reliably effective intervention for NAFLD. MCTs may offer a supplementary benefit, but they are not a shortcut around the fundamentals.
Chain length matters: Look for products that specify C8 (caprylic acid) and C10 (capric acid) content. Some cheaper MCT oils contain significant amounts of C12 (lauric acid), which does not share the same rapid oxidation pathway and behaves more like the long-chain fats your liver already has too much of.
Talk to your doctor if you have advanced liver disease: The animal evidence on fibrosis is intriguing but very early. People with diagnosed NASH, significant fibrosis, or cirrhosis should not self-treat with supplements based on mouse data alone.

Why the Human Trials Have Not Happened Yet

It is reasonable to wonder why, given the encouraging animal data, nobody has run a definitive human trial on MCT oil for fatty liver. Part of the answer is economic. MCT oil is an unpatentable commodity, and most large liver trials are funded by pharmaceutical companies developing patentable drugs. There is no financial incentive for a company to spend tens of millions of dollars proving that a cheap supplement works. The trials that do exist for MCT oil tend to be small and focused on outcomes like weight, cholesterol, or blood sugar rather than liver fat measured directly by imaging or biopsy.

Another factor is that the NAFLD field has been preoccupied with the development of dedicated pharmaceutical treatments. The first drug specifically approved for metabolic dysfunction-associated steatohepatitis (the newer name for NASH) arrived only recently, and the clinical trial infrastructure around liver disease has been oriented toward those drug-development programs. Dietary fat composition, while biologically interesting, has been a lower priority.

That said, the consistency of the animal evidence, the plausibility of the mechanisms, and the growing interest in dietary approaches to metabolic disease all suggest that human data will eventually come. Some researchers have pointed to the need for trials that use liver imaging or elastography to directly measure changes in liver fat and stiffness in response to MCT supplementation, rather than relying on blood markers alone.

How MCT Oil Fits into the Broader Dietary Picture

Even without dedicated NAFLD trials, there are ways to think about where MCT oil might fit in a diet aimed at liver health. The Mediterranean dietary pattern recommended by clinical guidelines emphasizes replacing saturated and processed fats with unsaturated sources like olive oil and fish.¹⁴ MCT oil does not neatly fit either category: it is a saturated fat, but one that the body handles very differently from the long-chain saturated fats in red meat and butter. It is burned quickly, produces ketones, and in animals at least, does not accumulate in liver tissue the way long-chain fats do.⁷

If you are following a Mediterranean-style diet and want to experiment with MCT oil, the most sensible approach is to use it as a partial replacement for other cooking fats or added fats, not as an addition. Replace a tablespoon of butter in your morning routine with a tablespoon of MCT oil and you keep the calorie count the same while potentially shifting the metabolic pathway through which those calories are processed. Whether that shift translates into measurable liver fat reduction in a human body is the question no one has formally answered yet, but the biochemistry and the animal data both point in a favorable direction.

1
PubMed Central. Molecular mechanisms of hepatic lipid accumulation in non-alcoholic fatty liver disease
2
PubMed Central. How does hepatic lipid accumulation lead to lipotoxicity in non-alcoholic fatty liver disease?
3
PubMed Central. Applications of Medium-Chain Triglycerides in Foods
4
The Journal of Nutrition. Relation of Ketosis to Metabolic Changes Induced by Acute Medium-Chain Triglyceride Feeding in Rats
5
PubMed Central. A high-fat diet supplemented with medium-chain triglycerides ameliorates hepatic steatosis by reducing ceramide and diacylglycerol accumulation in mice
6
PubMed. Medium chain triglycerides alleviate non-alcoholic fatty liver disease through bile acid-mediated FXR signaling pathway: A comparative study with common vegetable edible oils
7
PubMed. Medium chain triglycerides dose-dependently prevent liver pathology in a rat model of non-alcoholic fatty liver disease
8
PubMed Central. Dietary medium-chain fatty acids reduce hepatic fat accumulation via activation of a CREBH-FGF21 axis
9
PubMed Central. Protective Effects of Medium-Chain Triglycerides on the Liver and Gut in Rats Administered Endotoxin
10
PubMed Central. Dietary fat sources differentially modulate intestinal barrier and hepatic inflammation in alcohol-induced liver injury in rats
11
PubMed. Medium-Chain Fatty Acids Ameliorate Liver Fibrosis by Phosphorylating Hepatic Stellate Cell Forkhead Box Protein O1
12
Trends in Endocrinology & Metabolism. Dietary medium-chain triacylglycerols in metabolic regulation
13
PubMed Central. Effects of medium chain triglycerides supplementation on insulin sensitivity and beta cell function: A feasibility study
14
Obesity Facts. EASL-EASD-EASO Clinical Practice Guidelines for the Management of Non-Alcoholic Fatty Liver Disease
15
Journal of Nutritional Science. The effects of coconut oil intake on metabolic disorders and fatty liver disease in mice